Enasidenib (AG-221)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Enasidenib (AG-221), covering 2022-09-10 to 2022-09-10. Get the full timeline:
Most recent: Clinical Trial Update: An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation [Phase 3]